Traded Jan 12 · filed 3 days later
Derivative exercise or conversion — not an open-market buy.
Traded Dec 16, 2025 · Filed Dec 19, 2025
A Roivant Sciences director sold $6.31M of Roivant Sciences shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$6,305,750
Shares × reported transaction price
36 days after results of Nov 10, 2025, 52 days before results of Feb 6, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −4.3% | +0.4% | −4.8% |
| 30 days | +1.3% | +0.1% | +1.2% |
| 90 days | +23.1% | −4.3% | +27.4% |
| 180 days | +37.8% | +8.7% | +29.1% |
Past results only. Not a forecast.
Traded Jan 12 · filed 3 days later
Derivative exercise or conversion — not an open-market buy.
Eric Venker (President & Immunovant CEO) sold ~$4.38M of Roivant Sciences
Automatic saleTraded Jan 12 · filed 3 days later
Derivative exercise or conversion — not an open-market buy.